{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI.&page=2", "query": { "intervention": "FOLFIRI.", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI.&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T19:15:13.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02588105", "title": "Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD0156", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Folinic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 84, "start_date": "2015-11-10", "completion_date": "2022-07-26", "has_results": false, "last_update_posted_date": "2022-09-19", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 2, "location_summary": "Aurora, Colorado • New York, New York", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588105" }, { "nct_id": "NCT01946074", "title": "A Study of ABT-165 in Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "ABT-165", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 101, "start_date": "2013-08-08", "completion_date": "2022-09-28", "has_results": false, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946074" }, { "nct_id": "NCT00020488", "title": "Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020488" }, { "nct_id": "NCT01123876", "title": "Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 60, "start_date": "2010-03", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2021-08-02", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01123876" }, { "nct_id": "NCT02890355", "title": "FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2016-10-27", "completion_date": "2021-10-21", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 783, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 507 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890355" }, { "nct_id": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Ovarian Cancer", "Gastric Cancer", "Palpable Subcutaneous Malignant Lesions", "Renal Cell Carcinoma", "Melanoma", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Imiquimod Cream", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2019-04-26", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872947" }, { "nct_id": "NCT02482441", "title": "A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Relapsed Tumors", "Refractory Solid Tumors" ], "interventions": [ { "name": "OMP-131R10", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-07-16", "completion_date": "2018-03-28", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02482441" }, { "nct_id": "NCT03803553", "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colon Cancer", "Stage III Colon Cancer" ], "interventions": [ { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "ACTIVE SURVEILLANCE", "type": "OTHER" }, { "name": "Nivolumab Protocol", "type": "DRUG" }, { "name": "Encorafenib/Binimetinib/Cetuximab Protocol", "type": "DRUG" }, { "name": "Trastuzumab + Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2020-04-16", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03803553" }, { "nct_id": "NCT00615056", "title": "A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Bevacizumab (avastin)", "type": "DRUG" }, { "name": "FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])", "type": "DRUG" }, { "name": "AG-013736 (axitinib)", "type": "DRUG" }, { "name": "FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2008-03", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-04-19", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 61, "location_summary": "Mobile, Alabama • Antioch, California • Los Angeles, California + 39 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Antioch", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pleasant Hill", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00615056" }, { "nct_id": "NCT04299880", "title": "Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Oncology" ], "interventions": [ { "name": "Napabucasin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-02-24", "completion_date": "2021-05-30", "has_results": false, "last_update_posted_date": "2023-11-08", "last_synced_at": "2026-09-22T19:15:13.767Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Scarborough, Maine • Portland, Oregon", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04299880" } ] }